Distinguished in Pancreatic Islet Cell Tumor

Jean-luc L. Raoul

Nantes, FR 
Clinical Trials:Currently Recruiting for 1 Trial
Distinguished in Pancreatic Islet Cell Tumor
Nantes, FR 
OverviewLocationsClinical Research

Overview

Jean-luc Raoul practices in Nantes, France. Mr. Raoul is rated as a Distinguished expert by MediFind in the treatment of Pancreatic Islet Cell Tumor. His top areas of expertise are Liver Cancer, Pancreatic Islet Cell Tumor, Neuroendocrine Tumor, and Colorectal Cancer.

His clinical research consists of co-authoring 137 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 4 articles in the study of Pancreatic Islet Cell Tumor.

Gender
Male

Locations

Nantes, 44805, France
Other Locations
Saint Herblain, 44805, France
Castanet-tolosan, France
Angers, 49055, France
Rene, France
44800 St Herblain, Sete, 44800, France
Marseille, France
R&D Unicancer And Sorbonne Université, Dijon, France
Paris, 13008, France
Rennes, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver
Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver
Enrollment Status: Recruiting
Publish Date: July 09, 2025
Intervention Type: Drug
Study Drugs: Oxaliplatin intravenous, 5 Fu, Folinic Acid, Oxaliplatin intra-arterial, Panitumumab, Bevacizumab
Study Phase: Phase 3
Prospective, Multicenter, Randomized, Controlled Study Evaluating SIR-Spheres Y-90 Resin Microspheres Preceding Cisplatin-gemcitabine (CIS-GEM) Chemotherapy Versus CIS-GEM Chemotherapy Alone as First-line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma
Prospective, Multicenter, Randomized, Controlled Study Evaluating SIR-Spheres Y-90 Resin Microspheres Preceding Cisplatin-gemcitabine (CIS-GEM) Chemotherapy Versus CIS-GEM Chemotherapy Alone as First-line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma
Enrollment Status: Terminated
Publish Date: May 09, 2025
Intervention Type: Device, Drug
Study Drug: Cisplatin-Gemcitabine
Study Phase: Phase 2/Phase 3
A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) as First-line Treatment of Biliary Tract Cancer
A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) as First-line Treatment of Biliary Tract Cancer
Enrollment Status: Terminated
Publish Date: November 14, 2023
Intervention Type: Drug
Study Drugs: Bintrafusp Alfa, Gemcitabine, Cisplatin
Study Phase: Phase 2/Phase 3
A Phase II, Multicenter, Open-label Study to Investigate the Clinical Efficacy of M7824 Monotherapy in Participants With Locally Advanced or Metastatic Biliary Tract Cancer Who Fail or Are Intolerant to First-line Platinum-Based Chemotherapy
A Phase II, Multicenter, Open-label Study to Investigate the Clinical Efficacy of M7824 Monotherapy in Participants With Locally Advanced or Metastatic Biliary Tract Cancer Who Fail or Are Intolerant to First-line Platinum-Based Chemotherapy
Enrollment Status: Completed
Publish Date: October 25, 2023
Intervention Type: Drug
Study Drug: M7824
Study Phase: Phase 2
NP137 - An Open-label, First in Human, Phase I Trial Aiming to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of a Humanized Monoclonal Antibody Targeting Netrin 1 (NP137) in Patients With Advanced/Metastatic Solid Tumors.
NP137 - An Open-label, First in Human, Phase I Trial Aiming to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of a Humanized Monoclonal Antibody Targeting Netrin 1 (NP137) in Patients With Advanced/Metastatic Solid Tumors.
Enrollment Status: Completed
Publish Date: July 25, 2022
Intervention Type: Drug
Study Drug: NP137
Study Phase: Phase 1
A Multicentric, Prospective Cohort Study Aiming to Evaluate the Added Value of a Large Molecular Profiling Panel (Panel FoundationOne) Versus a Limited Molecular Profiling Panel (Panel CONTROL) in Advanced Solid Tumors.
A Multicentric, Prospective Cohort Study Aiming to Evaluate the Added Value of a Large Molecular Profiling Panel (Panel FoundationOne) Versus a Limited Molecular Profiling Panel (Panel CONTROL) in Advanced Solid Tumors.
Enrollment Status: Completed
Publish Date: May 09, 2022
Intervention Type: Genetic
Study Phase: Not Applicable
A Phase 2 Study of Aflibercept and Chemotherapy as First Line Treatment for Metastatic Colorectal Cancer Assessable With DCE-US.
A Phase 2 Study of Aflibercept and Chemotherapy as First Line Treatment for Metastatic Colorectal Cancer Assessable With DCE-US.
Enrollment Status: Terminated
Publish Date: October 20, 2021
Intervention Type: Drug
Study Phase: Phase 2
Prospective Randomized Study Comparing the Morbidity and Mortality After Liver Resection for Synchronous Colorectal Cancer Metastases When Performed Either During or 12 to 14 Weeks After the Primary Resection
Prospective Randomized Study Comparing the Morbidity and Mortality After Liver Resection for Synchronous Colorectal Cancer Metastases When Performed Either During or 12 to 14 Weeks After the Primary Resection
Enrollment Status: Terminated
Publish Date: March 11, 2019
Intervention Type: Procedure
Study Phase: Not Applicable
A Unicentric, Open Label, Mechanism of Action Trial, on the Biological Effect of Nab-paclitaxel Combined to Gemcitabine, in Patients With Metastatic Pancreatic Adenocarcinoma
A Unicentric, Open Label, Mechanism of Action Trial, on the Biological Effect of Nab-paclitaxel Combined to Gemcitabine, in Patients With Metastatic Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: March 28, 2017
Intervention Type: Drug
Study Phase: Phase 1
View 8 Less Clinical Trials

137 Total Publications

Progression-Free Survival Under Immune Checkpoint Inhibitors for Metastatic Non-Small-Cell Lung Cancer: A Retrospective Cohort Study.
Progression-Free Survival Under Immune Checkpoint Inhibitors for Metastatic Non-Small-Cell Lung Cancer: A Retrospective Cohort Study.
Journal: Oncology and therapy
Published: November 15, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Raoul's expertise for a condition
ConditionClose
    View All 24 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile